SUTENT (Pfizer Laboratories Div Pfizer Inc)
Welcome to the PulseAid listing for the SUTENT drug offered from Pfizer Laboratories Div Pfizer Inc. This Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Pfizer Laboratories Div Pfizer Inc |
NON-PROPRIETARY NAME: | Sunitinib malate |
SUBSTANCE NAME: | SUNITINIB MALATE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | CAPSULE |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2006-01-26 |
END MARKETING DATE: | 0000-00-00 |
SUTENT HUMAN PRESCRIPTION DRUG Details:
Item Description | SUTENT from Pfizer Laboratories Div Pfizer Inc |
LABELER NAME: | Pfizer Laboratories Div Pfizer Inc |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 12.5(mg/1) |
START MARKETING DATE: | 2006-01-26 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0069-0550_fc8fc988-6d68-4f7b-b274-dd332905ad3d |
PRODUCT NDC: | 0069-0550 |
APPLICATION NUMBER: | NDA021938 |
Other SUNITINIB MALATE Pharmaceutical Manufacturers / Labelers: